Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population.

BACKGROUND we explored serum 25-hydroxyvitamin D (25[OH]D) levels and associated factors for insufficiency or deficiency in an adult human immunodeficiency virus (HIV) cohort and compared 25(OH)D levels with those in the general US population. METHODS using baseline data from the Study to Understand the Natural History of HIV and AIDS in the Era of Effective Therapy (SUN), a prospective, observational cohort study of HIV-infected adults enrolled at 7 HIV specialty clinics in 4 US cities from March 2004 to June 2006, we estimated the prevalence of vitamin D insufficiency or deficiency (defined as 25(OH)D levels <30 ng/mL), standardized by age, race, and sex. Using multiple logistic regression, we examined risk factors for vitamin D insufficiency or deficiency. RESULTS among 672 SUN participants with baseline serum 25(OH)D determinations who were not receiving vitamin D supplements, 70.3% (95% confidence interval [CI], 68.1%-74.9%) were vitamin D insufficient or deficient, compared with 79.1% (95% CI, 76.7-81.3) of US adults. Factors associated with vitamin D insufficiency or deficiency included black race (adjusted odds ratio [aOR], 4.51; 95% CI, 2.59-7.85), Hispanic ethnicity (aOR, 2.78; 95% CI, 1.31-5.90), higher body mass index (aOR, 1.04; 95% CI, 1.00-1.09), hypertension (aOR, 1.88; 95% CI, 1.10-3.22), lack of exercise (aOR, 3.14; 95% CI, 1.80-5.47), exposure to efavirenz (aOR, 1.98; 95% CI, 1.18-3.34), higher exposure to ultraviolet light (aOR, .78; 95% CI, .71-.86), renal insufficiency (aOR, .55; 95% CI, .36-.83), and exposure to ritonavir (aOR, .56; 95% CI, .35-0.89). CONCLUSIONS similar to findings in US adults generally, vitamin D insufficiency or deficiency is highly prevalent among HIV-infected adults and is associated with known risk factors. Observed associations of vitamin D levels with renal insufficiency and with use of ritonavir- and efavirenz-containing regimens are consistent with both HIV-related and therapy-mediated alterations in vitamin D metabolism. Clinicians should consider screening all patients for vitamin D insufficiency or deficiency.

[1]  H. Bischoff-Ferrari,et al.  High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients , 2010, AIDS.

[2]  T. Brown,et al.  Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D , 2010, Antiviral therapy.

[3]  L. Hurley,et al.  Impact of Tenofovir on Renal Function in HIV-Infected, Antiretroviral-Naive Patients , 2010, Journal of acquired immune deficiency syndromes.

[4]  V. Preedy,et al.  National Health and Nutrition Examination Survey , 2010 .

[5]  E. Overton,et al.  Frailty among HIV-infected persons in an urban outpatient care setting. , 2009, The Journal of infection.

[6]  A. Copas,et al.  Tenofovir‐associated renal and bone toxicity , 2009, HIV medicine.

[7]  I. Lang,et al.  Serum 25-Hydroxyvitamin D Concentration and Cognitive Impairment , 2009, Journal of geriatric psychiatry and neurology.

[8]  G. Zoppini,et al.  No influence of nevirapine on vitamin D deficiency in HIV-infected patients. , 2009, AIDS research and human retroviruses.

[9]  G. D. De Socio,et al.  Efavirenz and bone health. , 2009, AIDS.

[10]  Carlos A Camargo,et al.  Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. , 2009, Archives of internal medicine.

[11]  G. Robbins,et al.  High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. , 2009, AIDS research and human retroviruses.

[12]  K. Arastéh,et al.  Efavirenz-induced osteomalacia. , 2009, AIDS.

[13]  K. Wood,et al.  The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN Study). , 2008, American journal of epidemiology.

[14]  S. Bandinelli,et al.  Association of low vitamin D levels with the frailty syndrome in men and women. , 2009, The journals of gerontology. Series A, Biological sciences and medical sciences.

[15]  Elizabeth A Yetley,et al.  Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. , 2008, The American journal of clinical nutrition.

[16]  F. Sweep,et al.  Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. , 2008, AIDS research and human retroviruses.

[17]  G. Curhan,et al.  Plasma 25-Hydroxyvitamin D Levels and Risk of Incident Hypertension Among Young Women , 2008, Hypertension.

[18]  K. Childs.  Should Vitamin D Be Prescribed with Tenofovir/FTC? , 2008 .

[19]  A. Grey,et al.  Osteomalacia in an HIV-infected man receiving rifabutin, a cytochrome P450 enzyme inducer: a case report , 2008, Annals of Clinical Microbiology and Antimicrobials.

[20]  A. Justice,et al.  Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Hang Lee,et al.  Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. , 2007, The Journal of clinical endocrinology and metabolism.

[22]  Keith C. Norris,et al.  Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. , 2007, Archives of internal medicine.

[23]  Edward Giovannucci,et al.  Plasma 25-Hydroxyvitamin D Levels and Risk of Incident Hypertension , 2007, Hypertension.

[24]  T. Brown,et al.  Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review , 2006, AIDS.

[25]  M. Sääf,et al.  Severe vitamin D deficiency diagnosed after introduction of antiretroviral therapy including efavirenz in a patient living at latitude 59 degrees N. , 2006, AIDS.

[26]  H. Valsamis,et al.  Antiepileptic drugs and bone metabolism , 2006, Nutrition & metabolism.

[27]  W. Willett,et al.  Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. , 2006, The American journal of clinical nutrition.

[28]  E. Villamor.  A potential role for vitamin D on HIV infection? , 2006, Nutrition reviews.

[29]  G. Aldrovandi,et al.  Vitamins D Status in adolescents and young adults with HIV infection , 2006, American Journal of Clinical Nutrition.

[30]  P. Lips,et al.  Estimates of optimal vitamin D status , 2005, Osteoporosis International.

[31]  Edward Giovannucci,et al.  The epidemiology of vitamin D and cancer incidence and mortality: A review (United States) , 2005, Cancer Causes & Control.

[32]  M. Saad,et al.  Hypovitaminosis D is associated with insulin resistance and β cell dysfunction , 2004 .

[33]  F. Chessa,et al.  Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[34]  J. Reynes,et al.  Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. , 2004, Journal of acquired immune deficiency syndromes.

[35]  Cecilia A. Hale,et al.  Calcium Absorption Varies within the Reference Range for Serum 25-Hydroxyvitamin D , 2003, Journal of the American College of Nutrition.

[36]  K. Yarasheski,et al.  HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D , 2003, AIDS.

[37]  R. Bouillon.  Vitamin D: From Photosynthesis, Metabolism, and action to Clinical Applications , 2001 .

[38]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[39]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[40]  its Panel on Folate,et al.  FOOD AND NUTRITION BOARD , 1998 .

[41]  P. Galan,et al.  Prevalence of Vitamin D Insufficiency in an Adult Normal Population , 1997, Osteoporosis International.

[42]  S. Frøland,et al.  Subnormal serum concentration of 1,25-vitamin D in human immunodeficiency virus infection: correlation with degree of immune deficiency and survival. , 1994, The Journal of infectious diseases.

[43]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[44]  Isma'il ibn Ali al-Sadiq.  AIDS , 1986, The Lancet.

[45]  T. Oppé,et al.  Vitamin D deficiency. , 1979, British medical journal.